Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.

In the vaginal dryness stratum, improvements in FSFI total score were numerically greater in women treated with ospemifene compared with placebo at Weeks 4 and 12 (LOCF); however, the difference did not reach statistical significance (data not shown).

also in 111,027 other papers